echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > 2021 ACR Annual Meeting: Systemic lupus erythematosus is a risk factor for death in elderly patients with early breast cancer

    2021 ACR Annual Meeting: Systemic lupus erythematosus is a risk factor for death in elderly patients with early breast cancer

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Purpose : Women with systemic lupus erythematosus (SLE) and breast cancer (BC) may receive different treatments (such as radiotherapy) than women with BC who do not have SLE .
    Women suffering from SLE and BC may have more comorbidities that affect survival .
    The goal of the study was to compare the survival rates of women with SLE and BC with women with BC alone or with SLE without cancer .

    PurposePurpose : Women with systemic lupus erythematosus (SLE) and breast cancer (BC) may receive different treatments (such as radiotherapy) than women with BC who do not have SLE .


    Women suffering from SLE and BC may have more comorbidities that affect survival .
    The goal of the study was to compare the survival rates of women with SLE and BC with women with BC alone or with SLE without cancer .

    Methods : The study included women ≥ 66 years of age who were diagnosed with BC between 2005 and 2015 , and a 5% non-cancer random sample living in the same area .


    According to the status of BC and SLE , the study subjects were divided into three groups: 1) BC SLE , 2) BC non- SLE , 3) non-cancer SLE .
    For women with BC , the study collected cancer characteristics (age and year at diagnosis, stage, hormone receptor status) and treatment (chemotherapy, radiotherapy, and type of surgery) .
    The cancer characteristics of BC SLE and BC non- SLE match .


     Methods The study included women ≥ 66 years of age who were diagnosed with diagnosed BC between 2005 and 2015 , and a 5% non-cancer random sample living in the same area .
    According to the status of BC and SLE , the study subjects were divided into three groups: 1) BC SLE , 2) BC non- SLE , 3) non-cancer SLE .
    For women with BC , the study collected cancer characteristics (age and year at diagnosis, stage, hormone receptor status) and treatment (chemotherapy, radiotherapy, and type of surgery) .
    The cancer characteristics of BC SLE and BC non- SLE match .
    Non-cancer SLE women matched the birth year and race of BC SLE .
    Kaplan-Meier method and multivariateThe Cox proportional hazards model is used to evaluate the association between survival outcomes and the Garris index (for SLE only ) group that adjusts for cancer characteristics and treatment (for BC ), comorbidities, and severity of SLE disease .


    ResultsResults : study identified 494 embodiment BC of SLE , 145517 embodiment BC non of SLE , and a matching of 268 cases of non-cancer of SLE


    ConclusionConclusion : The study data show that the suffering individual BC compared to patients suffering from BC and SLE patients at risk of earlier death, adjusting SLE risks remain after the disease activity and complications


    Bruera S, Lei X, Pundole X, Zhao H, Giordano S, Vinod S, Suarez-Almazor M.


    Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer [abstract].
    Arthritis Rheumatol.


    Bruera S, Lei X, Pundole X, Zhao H, Giordano S, Vinod S, Suarez-Almazor M.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.